News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2012 Archives

Nov 12, 2012

AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These...

More
Nov 11, 2012
Call Scheduled for Monday, November 12, 2012 at 8:15 AM EST/5:15 AM PST

Nektar Therapeutics (Nasdaq: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca. Howard Robin, president and...

More
Nov 7, 2012

Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the...

More
Nov 6, 2012

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012, after the close of U.S.-based financial...

More
Oct 15, 2012
NKTR-171 Demonstrates Dose-Dependent Analgesia with Significantly Reduced CNS-Related Side Effects in Preclinical Studies

Nektar Therapeutics (Nasdaq: NKTR) today announced that preclinical data for NKTR-171, a new investigational drug candidate to treat neuropathic pain, was presented at the 41st Annual Meeting of...

More
Sep 18, 2012
Nektar Announces Start of Second Phase 1a Clinical Study to Evaluate Pharmacodynamics of NKTR-192 in Humans

Nektar Therapeutics (Nasdaq: NKTR) announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic...

More
Sep 13, 2012

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2012 Global Life Sciences Conference in New York at the...

More
Aug 9, 2012

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2012. Cash, cash equivalents, and investments at June 30, 2012 were $477.1 million as...

More
Aug 7, 2012

Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at Stanford...

More
Aug 2, 2012

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012, after the close of U.S.-based financial markets....

More
Jul 24, 2012

Nektar Therapeutics (NASDAQ: NKTR) announced today that the first patient has been enrolled in a Phase 2 clinical study of NKTR-181, a new, first-of-its-kind, opioid analgesic candidate. NKTR-181...

More
Jul 10, 2012

Nektar Therapeutics (Nasdaq: NKTR) today announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering exempt from the registration requirements of the...

More
Jun 7, 2012

Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track development program for the treatment of moderate to...

More
May 30, 2012

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York...

More
May 2, 2012

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012. Cash, cash equivalents, and investments at March 31, 2012 were $498.8 million as...

More
Apr 25, 2012

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the close of U.S.-based financial markets. Howard...

More
Apr 10, 2012

Nektar Therapeutics (Nasdaq: NKTR) will host an Investor and Analyst R&D Day for its institutional investors and research analysts on Monday, April 16, 2012 from 12:00 p.m. to 5:00 p.m. ET in New...

More
Apr 2, 2012

Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's...

More
Mar 28, 2012

Nektar Therapeutics (NASDAQ: NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved OMONTYS® (peginesatide) Injection for the...

More
Mar 20, 2012
Huntsville, Alabama Will Continue to Serve as Company's Manufacturing and Process Development Center

Nektar Therapeutics (NASDAQ:NKTR) today announced that the company is consolidating its U.S.-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is...

More
Mar 2, 2012

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will webcast its presentation at the 32nd Annual Cowen and Company Healthcare Conference to be held at the Boston Marriott Copley Place...

More
Feb 29, 2012

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2011. Cash, cash equivalents, and investments at December 31, 2011 were...

More
Feb 29, 2012

Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®,...

More
Feb 27, 2012
NKTR-181 demonstrates reduced rate of entry into CNS, sustained analgesic responses, and excellent tolerability profile in humans

Nektar Therapeutics (Nasdaq: NKTR) today announced a presentation of positive clinical data for NKTR-181, its new oral opioid analgesic molecule, at the 2012 American Academy of Pain Medicine's...

More
Feb 24, 2012

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2011 on Wednesday, February 29, 2012, after the close of U.S.-based financial...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide